Heron Therapeutics is trading 5.84% higher at $0.38 alongside broader market gains; no direct catalyst was established.
- No new company-specific announcement was identified for October 2; the latest archive release is dated August 10.
- The S&P 500 is up 0.98%, Nasdaq 1.65%, and Dow 0.54%; the weak September jobs report and easing rate concerns supported risk appetite.
- The Long Grove licensing agreement was announced September 29; available evidence does not establish it as the direct cause.